A new study by Mayo Clinic researchers has identified that a chromosome instability gene, USP24, is frequently missing in pediatric patients with neuroblastoma, an aggressive form of childhood cancer. The finding provides important insight into the development of this disease. The study is published in Cancer Research, the journal of the American Association for Cancer Research.
Immunocore Limited: Immunocore announces key appointments to management and Board
Ralph Torbay appointed Head of Commercial to spearhead the launch of tebentafusp
Dr. Roy S. Herbst appointed as a Non-Executive Director to the Board
OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US - 16 February 2021 - Immunocore Holdings plc (Nasdaq: IMCR), (or the Company or Immunocore ), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announces the appointment of Ralph Torbay as its new Head of Commercial and the appointment of Dr. Roy S. Herbst as a member of its Board of Directors, effective January 28, 2021.
Researchers develop new test to help fight deadly melanoma ANI | Updated: Feb 16, 2021 06:00 IST
Washington [US], February 16 (ANI): Researchers have developed a prototype test that can help identify if patients with deadly metastasised melanoma are likely to benefit from immunotherapy.
Australian researchers from QIMR Berghofer Medical Research Institute conducted the study. Details about the test and the research have been published on Monday (local time) in Clinical Cancer Research, a journal of the American Association for Cancer Research.
The prototype test detects levels of the protein LC3B on cancer cells. High levels of LC3B are associated with better patient responses to a form of treatment known as checkpoint inhibitor immunotherapy.
E-Mail
IMAGE: Cancer evades the immune system by feeding the T cells that protect the tumor and starving the T cells that would attack. view more
Credit: UPMC, created with BioRender.com
PITTSBURGH, Feb. 15, 2021 - A paper published today in
Nature shows how chemicals in the areas surrounding tumors known as the tumor microenvironment subvert the immune system and enable cancer to evade attack. These findings suggest that an existing drug could boost cancer immunotherapy.
The study was conducted by a team of scientists at UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine, led by Greg Delgoffe, Ph.D., Pitt associate professor of immunology. By disrupting the effect of the tumor microenvironment on immune cells in mice, the researchers were able to shrink tumors, prolong survival and increase sensitivity to immunotherapy.
Date Time
Researchers identify gene implicated in neuroblastoma, a childhood brain cancer
A new study by Mayo Clinic researchers has identified that a chromosome instability gene, USP24, is frequently missing in pediatric patients with neuroblastoma, an aggressive form of childhood brain cancer. The finding provides important insight into the development of this disease. The study is published in Cancer Research, the journal of the American Association for Cancer Research.
International Childhood Cancer Awareness Day – Feb. 15, 2021
“Neuroblastoma is a highly aggressive cancer that nearly exclusively affects young children,” says Paul Galardy, M.D., a pediatric hematologist and oncologist at Mayo Clinic. Despite the use of multiple treatment approaches, Dr. Galardy says many children die of this disease every year.